September 3rd 2025
External validation will be assessed in cohort 2 of the AURORAX-0087A trial to improve recurrence detection for clear cell renal cell carcinoma.
August 18th 2025
Patients with muscle-invasive bladder cancer with a positive Signatera test displayed a significant improvement in disease-free and overall survival.
August 7th 2025
Adverse reactions in the phase 3 ENVISION trial were largely mild to moderate in severity, and serious reactions occurred in 12% of those with NMIBC.
June 18th 2025
The FDA did not expand the indication to include patients with non–homologous recombination repair gene mutated castration-resistant prostate cancer.
June 4th 2025
A machine learning-based approach found that evaluating multiple biomarker features may identify outcomes and treatment resistance in renal cell carcinoma.
CAN-2409/EBRT Improves Disease-Free Survival in Localized Prostate Cancer
The addition of CAN-2409 to a prodrug and radiation therapy in intermediate-to-high-risk prostate cancer significantly improved cancer-specific outcomes.
Second-Line Cabozantinib Regimens Exhibit Efficacy in Advanced RCC
Efficacy and safety outcomes in the phase 3 CONTACT-03 study were consistent regardless of patients' prior immunotherapy or tyrosine kinase inhibitor use.
ODAC Votes 8-to-0 Against First-Line Talazoparib/Enzalutamide in mCRPC
Eight votes were cast against the favorability of talazoparib and enzalutamide in the first-line setting for patients with metastatic castration-resistant prostate cancer.
FDA Approves Belzutifan in Adult/Pediatric Pheochromocytoma and Paraganglioma
Data from the LITESPARK-015 trial supported the FDA’s decision to approve belzutifan monotherapy in patients with advanced, unresectable, or metastatic PPGL.
Durvalumab Combo Demonstrates DFS Improvement in High-Risk NMIBC
Data from the POTOMAC trial evaluating durvalumab in NMIBC will be presented at a future medical meeting and shared with global regulatory authorities.
EVP Before Consolidative Surgery Optimizes Responses in Urothelial Cancer
No 90-day mortality was observed among patients who were treated with EVP followed by surgery for advanced urothelial cancer.
Cretostimogene Grenadenorepvec Displays Efficacy in BCG-Unresponsive NMIBC
Complete response rates were observed consistently across patient subgroups in those with high-risk BCG-unresponsive non-muscle invasive bladder cancer.
Chemoradiation Prolongs OS, Maintains QOL in Advanced Gallbladder Cancers
Chemoradiotherapy resulted in lower incidence of local progression, prompting an evaluation of resectability in patients with advanced gallbladder cancers.
A World of Research, Care, and Science: Becoming A Radiation Oncologist
James B. Yu, MD, MHS, FASTRO, didn’t always envision himself as a radiation oncologist, but now works tirelessly to treat patients and advance research for genitourinary cancers.
The Effect of Dato-DXd Targeting TROP2 in Urothelial Cancer
Funda Meric-Bernstam, MD, spoke about the TROPION-PanTumor01 trial results and the TROP2 targeting nature of dato-DXd in patients with heavily pretreated, metastatic urothelial cancer.
Disease Progression Links to QOL With Cemiplimab/Chemo in Penile Carcinoma
There were no new safety signals with cemiplimab plus chemotherapy in the phase 2 EPIC-A trial, Challapalli stated.
Top 5 Takeaways for Genitourinary Cancer Care From 2025 ASCO GU
Data presented at 2025 ASCO GU reinforce the use of agents like nivolumab, cabozantinib, and darolutamide across different genitourinary malignancies.
Positive Efficacy Noted With Cemiplimab/Chemotherapy in Penile Carcinoma
The phase 2 EPIC trial assessing patients with penile carcinoma met its primary end point of clinical benefit rate, with the lower bound of the confidence interval exceeding the null hypothesis limit.
Promising Clinical Activity in UTUC Lesions With Enfortumab Vedotin Plus Pembrolizumab
New data from a small retrospective analysis showed activity with enfortumab vedotin and pembrolizumab in UTUC lesions.
A Look at Upcoming Impactful Presentations at ASCO GU 2025
The 2025 Genitourinary Cancers Symposium will feature key updates in the management of different bladder, prostate, and kidney cancer populations.
Enfortumab Vedotin Combo Gains European Approval for Urothelial Cancer
The decision follows phase 3 EV-302 trial findings showing improved survival with enfortumab vedotin plus pembrolizumab vs chemotherapy in urothelial cancer.
Frontline Nivolumab Combo Improves TFS Vs Sunitinib in Advanced RCC
Additionally, the 48-month overall survival rate was higher with nivolumab/cabozantinib vs sunitinib in the phase 3 CheckMate 9ER trial.
Lenvatinib Combo Improves Clinical Benefit in Clear Cell RCC Subgroups
Additionally, PFS data in the CLEAR trial confirm the benefit of the lenvatinib combination in patients with clear cell RCC regardless of PD-L1 IHC.
HK2-Targeting Radioligand Shows Responses With Some AEs in Metastatic CRPC
Thrombocytopenia and interstitial lung disease following treatment with JNJ-6420 appeared to be manageable with dose schedule modifications.
Pembrolizumab Combo Yields Efficacy in Penile Squamous Cell Carcinoma
Pembrolizumab plus platinum-containing therapy may be a new treatment option for advanced penile cancer based on data from the HERCULES trial.
Novel PROTAC Androgen Receptor Elicits Clinical Activity in Metastatic CRPC
Phase 1/2 data support further development of ARV-766 in advanced prostate cancer, says Daniel P. Petrylak, MD.
Time to Progression in mHSPC Cohort Prolonged With Darolutamide
The rate of subsequent anticancer therapy was reduced with darolutamide vs placebo in patients with mHSPC in the ARASENS trial.
Circulating KIM-1 May Predict Benefit With Atezolizumab in RCC
KIM-1 was the most significantly enriched circulating protein in recurrence vs baseline serum samples among patients in the IMmotion010 trial.
Extending the Benefits of Avelumab Maintenance in Urothelial Carcinoma
Ongoing research may clarify the potential benefit of avelumab when administered in combination with other agents in advanced urothelial carcinoma.
Predicting Responses to Sacituzumab Govitecan Combo in Urothelial Cancer
Spatial analyses may help determine factors that influence responses to sacituzumab govitecan-containing regimens in urothelial carcinoma.
Enfortumab Vedotin Shows Activity in Cisplatin-Ineligible MIBC
Less than half of the patients enrolled on cohort H of the EV-103 trial required subsequent anticancer therapy following enfortumab vedotin.
nmHSPC QOL Remains Consistent After Enzalutamide Schedule Modifications
Data from the EMBARK trial show no significant differences in sexual activity and urinary symptoms when suspending treatment with enzalutamide.
Exploring The Use of Enfortumab Vedotin in Rare Genitourinary Cancers
Attending educational sessions may help with understanding how to manage toxicities associated with enfortumab vedotin in rare genitourinary cancers.
Determining Personal and Professional Work/Life Balance in GU Oncology
Two women in genitourinary oncology discuss their experiences with figuring out when to begin a family and how to prioritize both work and children.
Observing the Evolving Prostate Cancer Landscape and Hopes for the Future
Over the past few decades, the prostate cancer space has evolved with increased funding for clinical trial creation and enrollment.